Gapping up
In reaction to strong earnings/guidance: ACI +26.5%, PGN +12.5%, AVEO +12.2%, RXDX +8.5%, DF +7.8%, HZNP +6.1%, ICON +5.8%, SNI +4.2%, INO +4%, RLD +3.6%, NSAM +2.5%, CTCM +2.4%, ENDP +1.9%, EXXI +1%
M&A news: PCL +14% (Weyerhaeuser and Plum Creek (PCL) to merge; all-stock transaction followed by $2.5 bln post-closing share repurchase; WY to review strategic alternatives for its Cellulose Fibers business)
Select metals/mining stocks trading higher: RGLD +1.4%, RIO +0.9%, SSRI +0.7%, AEM +0.7%, KGC +0.6%, GG +0.5%
Select oil/gas related names showing strength: APA +12.9% (still checking), RIG +2.3% (still checking), SDRL +2.2% (still checking), OAS +2% (still checking), STO +1.8% (still checking), NBL +1% (still checking), RDS.A +0.8% (still checking)
Other news: AVXL +20.7% (presents positive safety and cognitive efficacy data for ANAVEX 2-73; study met the primary objective of safety), PCL +14% (Weyerhaeuser and Plum Creek (PCL) to merge; all-stock transaction followed by $2.5 bln post-closing share repurchase; WY to review strategic alternatives for its Cellulose Fibers business), TKAI +13.4% (presents new data highlighting the anti-tumor activity of galeterone in multiple preclinical tumor models), IMNP +9.6% (announces FDA acceptance of its IND application for Bertilimumab, to treat Bullous Pemphigoid; enables expanded recruitment for its clinical trials), RXDX +8.5% (reports interim data from RXDX-105 Phase 1 clinical trial; RXDX-105 was well tolerated to date), WTW +6.3% (cont strength), RDHL +4.5% (RedHill Biopharma and IntelGenx Corp announce that they have been granted marketing approval in Germany, for Rizaport 5mg and 10mg to treat migraines), CRIS +4% (presents preclinical data from oral small molecule PD-L1/VISTA and IRAK4 programs), MT +2.8% (Telegraph discusses that Europe wants China to stop dumping steel output), ERIC +2.2% (Cisco Systems and Ericsson form strategic partnership), COLL +1.8% (announces FDA approval for its NDA for Xtampza ER), GALE +1.7% (reports data from its GALE-301 and GALE-302 clinical programs)
Analyst comments: AEZS +24.6% (upgraded to Buy at Canaccord Genuity), PZZA +3.2% (upgraded to Overweight at KeyBanc
)
In reaction to strong earnings/guidance: ACI +26.5%, PGN +12.5%, AVEO +12.2%, RXDX +8.5%, DF +7.8%, HZNP +6.1%, ICON +5.8%, SNI +4.2%, INO +4%, RLD +3.6%, NSAM +2.5%, CTCM +2.4%, ENDP +1.9%, EXXI +1%
M&A news: PCL +14% (Weyerhaeuser and Plum Creek (PCL) to merge; all-stock transaction followed by $2.5 bln post-closing share repurchase; WY to review strategic alternatives for its Cellulose Fibers business)
Select metals/mining stocks trading higher: RGLD +1.4%, RIO +0.9%, SSRI +0.7%, AEM +0.7%, KGC +0.6%, GG +0.5%
Select oil/gas related names showing strength: APA +12.9% (still checking), RIG +2.3% (still checking), SDRL +2.2% (still checking), OAS +2% (still checking), STO +1.8% (still checking), NBL +1% (still checking), RDS.A +0.8% (still checking)
Other news: AVXL +20.7% (presents positive safety and cognitive efficacy data for ANAVEX 2-73; study met the primary objective of safety), PCL +14% (Weyerhaeuser and Plum Creek (PCL) to merge; all-stock transaction followed by $2.5 bln post-closing share repurchase; WY to review strategic alternatives for its Cellulose Fibers business), TKAI +13.4% (presents new data highlighting the anti-tumor activity of galeterone in multiple preclinical tumor models), IMNP +9.6% (announces FDA acceptance of its IND application for Bertilimumab, to treat Bullous Pemphigoid; enables expanded recruitment for its clinical trials), RXDX +8.5% (reports interim data from RXDX-105 Phase 1 clinical trial; RXDX-105 was well tolerated to date), WTW +6.3% (cont strength), RDHL +4.5% (RedHill Biopharma and IntelGenx Corp announce that they have been granted marketing approval in Germany, for Rizaport 5mg and 10mg to treat migraines), CRIS +4% (presents preclinical data from oral small molecule PD-L1/VISTA and IRAK4 programs), MT +2.8% (Telegraph discusses that Europe wants China to stop dumping steel output), ERIC +2.2% (Cisco Systems and Ericsson form strategic partnership), COLL +1.8% (announces FDA approval for its NDA for Xtampza ER), GALE +1.7% (reports data from its GALE-301 and GALE-302 clinical programs)
Analyst comments: AEZS +24.6% (upgraded to Buy at Canaccord Genuity), PZZA +3.2% (upgraded to Overweight at KeyBanc
)